JonesResearch assumed coverage of Evaxion Biotech (EVAX) with a Buy rating and $10 price target The firm says the company uses its AI-driven platform to design novel oncology and infectious disease vaccines. Evaxion’s “promising” melanoma asset is likely to attract strategic interest, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech price target lowered to $9 from $11 at Lake Street
- Evaxion Posts Transformational 2025, Extends Cash Runway Into 2027 on MSD Deal and Vaccine Progress
- Evaxion Biotech reports Q4 EPS (2c) vs. (21c) last year
- Evaxion Biotech sees FY26 capex ‘similar’ to FY25
- Evaxion Biotech sees cash runway into 2H27